决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.
Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.
我们的结果提示,B7-H3-CAR-T 疗法联合放疗可能是治疗实体瘤的一种有前景的方式。
目的:CAR-T(CAR-T)细胞治疗实体瘤的疗效有限,主要原因是肿瘤抗原异质性及免疫抑制性肿瘤微环境(TME)。B7-H3 在多数类型的实体瘤中过表达,是有前景的肿瘤治疗靶点。本研究旨在探讨放疗联合 B7-H3-CAR-T 治疗实体瘤模型的效果。方法:制备并检测经照射的肿瘤细胞系,构建人源化 B7-H3-CAR-T,并在体外和体内评估放疗预处理对 B7-H3-CAR-T 靶向实体瘤模型的细胞毒作用的影响。结果:照射显著提高了人胰腺癌(PANC-1)、结直肠癌(HCT-15、SW620)、急性髓细胞白血病(AML-5)、表皮样癌(KB)和胶质瘤(U87-MG)细胞系中的 B7-H3 表达。6 Gy 照射还上调了 HCT-15 细胞中的肿瘤浸润相关分子,如细胞间黏附分子-1(ICAM-1)或 FAS,提示放疗可能产生协同增强作用。体外和体内实验表明,照射确实显著增强了 CAR-T 浸润肿瘤并杀伤肿瘤的能力。有趣的是,在双瘤小鼠模型中,照射侧的肿瘤细胞被完全清除;照射还增强了 CAR-T 对未照射侧肿瘤的杀伤能力,证实放疗联合 CAR-T 治疗存在远隔效应。结论:放疗联合 B7-H3-CAR-T 可能是治疗实体瘤的一种有前景的方式。
AIMS: Limited efficacy of chimeric antigen receptor T (CAR-T) cells in treating solid tumors is largely due to the antigen heterogeneity and immunosuppressive tumor microenvironment (TME). B7-H3 is over-expressed in most kind of solid tumors, making it a promising target for cancer treatment. This study aims to explore the effect of B7-H3-CAR-T therapy combined with radiotherapy in treating solid tumor models. METHODS: Irradiated tumor cell lines were prepared and tested. A humanized B7-H3-CAR-T was constructed, and it was evaluated that B7-H3-CAR-T cytotoxicity against solid tumor models with preconditioning of radiotherapy in vitro and vivo. RESULTS: Irradiation was found to increase expression level of B7-H3 in pancreatic cancer (PANC-1), colorectal cancer (HCT-15, SW620), acute myelocytic leukemia (AML-5), epidermoid carcinoma (KB) and glioma (U87-MG) human cell lines significantly. 6Gy irradiation was also found to up-regulate tumor-infiltration molecule like intracellular adhesion molecule-1 ICAM-1 or FAS in HCT-15 cells, supporting a possible synergistic enhancement effect of radiotherapy. In vitro and in vivo experiments demonstrated that irradiation indeed significantly enhanced the ability of B7-H3-CAR-T to infiltrate and kill tumors. Interestingly in dual-tumor mouse model study, not only tumor cells on irradiation side were eradicated completely, irradiation also enhanced CAR-T tumor-killing ability on non-irradiated side, confirming the abscopal effect of irradiation existed with CAR-T therapy. CONCLUSIONS: Our results suggest that B7-H3-CAR-T therapy combined with radiotherapy may be a promising modality in treating solid tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。